Episode 164: Every angle on the FDA's polarizing approval of Biogen's Alzheimer's drug
We're devoting this entire episode to the FDA's p…
June 10, 202140m 48s
Audio is streamed directly from the publisher (traffic.megaphone.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
We're devoting this entire episode to the FDA's polarizing decision to approve Aduhelm, a controversial Biogen treatment for Alzheimer's disease. First, we'll break down what happened and why it's such a big deal, and then we'll talk about the broader implications for science, medicine, and the drug industry as a whole. Finally, we'll zoom out explore how the FDA got to this moment in a conversation with Yale University professor and global health activist Gregg Gonsalves.